BC Cancer Agency Tumor Tissue Repository, Canada

Certification Status: Approved

Registration Status: Completed

Objective: The BC Cancer Agency Tumor Tissue Repository (TTR) is a provincial program established by the BC Cancer Agency which provides cancer care for the 4.3 million population of British Columbia, Canada. The TTR program comprises framework initiatives (national and provincial), research biobanking support for specific affiliated projects and provincial BCCA affiliated biobanks, and a core TTR biobank with primary accrual and biospecimen processing and storage laboratory site at the BCCA Vancouver Island Center, Victoria, and a database core located at the BCCA Vancouver Center, Vancouver. The goal of this biobank program is to collect biospecimens and health data from consenting donors in BC and to process, annotate, and provide these materials to support a spectrum of cancer research, including biomarker discovery and validation, and to promote the development of targeted cancer therapies.

Registered Biobank Name	BC Cancer Agency Tumor Tissue Repository (BCCA-TTR)
Biobank Leader	Sheila O'Donoghue
Country	Canada
Email for biobank inquiries	sodonoghue@pathology.ubc.ca
Principal Investigator	Dr Peter Watson
Website	http://www.bccrc.ca/dept/ttr
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Poly - Collection aimed at supporting undetermined, multiple users with ethics approved research projects, through a defined access/application mechanism.

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).